IGM Biosciences Inc (IGMS NASDAQ) stock market data APIs
$1.11
-0.02(-1.8%)
as of June 30, 2025
Try our APIs with
free plan!
IGM Biosciences Inc Financial Data Overview
Price chart is built with
Anychart
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Prev. Close
1.11
Open
1.0903
High
1.1668
Low
1.0903
52 wk Range
0.92-22.5
Market Cap
64 924 K
Shares Outstanding
34 728 K
Revenue
2 681 K
EPS
-0.86
Beta
0.511
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get IGM Biosciences Inc data using free add-ons & libraries
Get IGM Biosciences Inc Fundamental Data
IGM Biosciences Inc Fundamental data includes:
- Net Revenue: 2 681 K
- EBITDA: -162 344 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-06
- EPS/Forecast: -0.45
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
IGM Biosciences Inc News
New
Igm biosciences CFO Tahir Misbah sells $1,825 in stock
igm biosciences (NASDAQ:IGMS) Chief Financial Officer Misbah Tahir sold 1,522 shares of the company’s common stock on June 16, 2025. The sales were executed at prices ranging from $1.17 to $1.22, wi...
Igm Biosciences chief business officer Decker sells $1,140 in stock
Lisa Lynn Decker, Chief Business Officer of IGM Biosciences (NASDAQ:IGMS), sold 951 shares of common stock on June 16, 2025. The transaction comes as the company’s stock has declined over 83% in the...
IGM Biosciences price target lowered to $1 from $2 at Truist
Truist lowered the firm’s price target on IGM Biosciences (IGMS) to $1 from $2 and keeps a Hold rating on the shares. The firm has updated tis model to reflect Q1 financial results and the company�...
IGM Bio (IGMS) Stock Rallies 142% in 3 Months: Here's Why
IGM Biosciences IGMS, a clinical-stage company, is developing a pipeline of Immunoglobin M (IgM) antibody-based candidates to treat patients with cancer and autoimmune and inflammatory diseases. The ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
